3/25/2013

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Biogen Idec's Tecfidera, or BG-12, and Sanofi's Aubagio as treatments for multiple sclerosis. If approved, the two oral drugs will compete with Novartis' Gilenya.

Related Summaries